Cargando…
Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway
BACKGROUND: Osteoporosis is a very common skeletal disorder that increases the risk of fractures. However, the treatment of osteoporosis is challenging. Hypoxia-inducible factor-1α (HIF-1α) plays an important role in bone metabolism. Roxadustat is a novel HIF stabilizer, and its effects on bone meta...
Autores principales: | Li, Luyao, Li, Afang, Zhu, Li, Gan, Liangying, Zuo, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124388/ https://www.ncbi.nlm.nih.gov/pubmed/35597989 http://dx.doi.org/10.1186/s13018-022-03162-w |
Ejemplares similares
-
The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1(+) Cells
por: Jatho, Aline, et al.
Publicado: (2022) -
Synergistic Inhibition of Wnt Pathway by HIF-1α and Osteoblast-Specific Transcription Factor Osterix (Osx) in Osteoblasts
por: Chen, Dafu, et al.
Publicado: (2012) -
HIF-1α Inhibits Wnt Signaling Pathway by Activating Sost Expression in Osteoblasts
por: Chen, Dafu, et al.
Publicado: (2013) -
HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis
por: Su, Xiaodong, et al.
Publicado: (2022) -
Repression of Osteoblast Maturation by ERRα Accounts for Bone Loss Induced by Estrogen Deficiency
por: Gallet, Marlène, et al.
Publicado: (2013)